FDA Approves Sotatercept-csrk for Pulmonary Arterial Hypertension
The FDA has approved Merck’s sotatercept-csrk (Winrevair) for the treatment of pulmonary arterial hypertension (PAH) in adults. The treatment is intended to increase exercise capacity, improve WHO functional class, and reduce the risk of clinical worsening …